Jennifer Lynn

Founder and CEO, Ashlins Pharmaceuticals · 1 appearance on the record.

computed by AI from the episodes · how this works → · full disclaimer →

founderexecutiveashlinspharma.com ↗

Jennifer Lin is a Thiel Fellow and biotechnology entrepreneur dedicated to developing and repurposing therapies for rare diseases. After establishing AUG Therapeutics to advance late-stage candidates for leukocyte adhesion deficiency type II, she founded Ashlins Pharmaceuticals to in-license clinically validated assets for formal FDA approval.

2statements → 1claims → 1claims resolved → 4/5average certainty → 1/5average debate potential →

1 supported 0 partly supported 0 contradicted how the 1 claim stands · each chip opens the sources

1 assertion · 1 insight · every statement was checked. The predictions and assertion are the 1 claim: statements the public record can support or contradict. 1 is resolved. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Jennifer argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Assertion Supported
New FDA Guidance Reduces Animal Testing Requirements for Antibody Biologics
“So they just recently released the guidance that certain biologic drugs, antibodies don't have to go after as much animal testing. You can leverage a lot of human clinical trials, which is like almost incorporating common sense, right?”
Jennifer Lynn May 28, 2025 ▶ 1:20:37 We Interviewed the New Thiel Fellow Dropouts

How they sound: not measured why? →

We measure speaking style by listening to the audio itself, and a fair number needs at least 2,000 words from one person on tape we have measured. There is too little of Jennifer Lynn on measured tape to publish a rate. This says nothing about how they speak.

Everything Jennifer Lynn said on TBPN that made the record, most notable first. Filter by type, assessment or year in the ledger →

Assertion Supported
New FDA Guidance Reduces Animal Testing Requirements for Antibody Biologics
“So they just recently released the guidance that certain biologic drugs, antibodies don't have to go after as much animal testing. You can leverage a lot of human clinical trials, which is like almost incorporating common sense, right?”
Jennifer Lynn May 28, 2025 ▶ 1:20:37 We Interviewed the New Thiel Fellow Dropouts
Insight
Repurposing Off-Patent Drugs Derisks Safety Hurdles for Rare Diseases
“Repurposing old drugs is a great strategy because you have safety usually already established for patients. Now you just have to work on making sure that it's like a drug that works.”
Jennifer Lynn May 28, 2025 ▶ 1:18:11 We Interviewed the New Thiel Fellow Dropouts

Appearances (1)

EpisodeDateSpeaking time
We Interviewed the New Thiel Fellow Dropouts May 28, 2025 5m
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 500 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.